Aarkstore - Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023
The new PharmaPoint Drug Evaluation report, “Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023”. For more details : http://goo.gl/jGIpRr
The new PharmaPoint Drug Evaluation report, “Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023”. For more details : http://goo.gl/jGIpRr
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
For More Information Visit : www.aarks<strong>to</strong>re.com<br />
Healthcare <strong>Market</strong> Research<br />
Reports
Summary<br />
GlobalData has released its new PharmaPoint Drug Evaluation report, “<strong>Lonsurf</strong><br />
(<strong>Colorectal</strong> <strong>Cancer</strong>) - <strong>Forecast</strong> <strong>and</strong> <strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2023</strong>”. <strong>Colorectal</strong> cancer<br />
(CRC) is the second leading cause of mortality among cancer patients in the world <strong>and</strong> is<br />
the third most diagnosed cancer globally, <strong>and</strong> thus represents a huge burden on<br />
healthcare systems. This report focuses on the current treatment l<strong>and</strong>scape, unmet<br />
needs, current pipeline, <strong>and</strong> commercial opportunities in the colorectal cancer market,<br />
with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-,<br />
second-, third-line KRAS wild-type <strong>and</strong> mutation-positive, <strong>and</strong> fourth-line metastatic.<br />
In terms of targeted treatments, the metastatic CRC treatment l<strong>and</strong>scape is mature,<br />
including the br<strong>and</strong>ed treatments Avastin (bevacizumab), Erbitux (cetuximab), <strong>and</strong><br />
Vectibix (panitumumab), treatments that have extended the survival of metastatic<br />
patients compared <strong>to</strong> chemotherapy-only regimens. However, high unmet needs remain<br />
for the extension of survival of metastatic patients, <strong>and</strong> particularly those with KRAS<br />
mutation-positive disease, for whom the epidermal growth fac<strong>to</strong>r recep<strong>to</strong>r (EGFR)<br />
inhibi<strong>to</strong>rs Erbitux <strong>and</strong> Vectibix are not recommended.<br />
For More Information Visit : www.aarks<strong>to</strong>re.com
Scope<br />
- Overview of <strong>Colorectal</strong> <strong>Cancer</strong>, including epidemiology, etiology, symp<strong>to</strong>ms, diagnosis,<br />
pathology <strong>and</strong> treatment guidelines as well as an overview on the competitive<br />
l<strong>and</strong>scape.<br />
- Detailed information on <strong>Lonsurf</strong> including product description, safety <strong>and</strong> efficacy<br />
profiles as well as a SWOT analysis.<br />
- Sales forecast for <strong>Lonsurf</strong> for the <strong>to</strong>p eight countries from 2013 <strong>to</strong> <strong>2023</strong>.<br />
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan<br />
<strong>and</strong> China.<br />
For More Information Visit : www.aarks<strong>to</strong>re.com
Reasons <strong>to</strong> buy<br />
- Underst<strong>and</strong> <strong>and</strong> capitalize by identifying products that are most likely <strong>to</strong> ensure a<br />
robust return<br />
- Stay ahead of the competition by underst<strong>and</strong>ing the changing competitive l<strong>and</strong>scape<br />
for <strong>Colorectal</strong> <strong>Cancer</strong><br />
- Effectively plan your M&A <strong>and</strong> partnership strategies by identifying drugs with the<br />
most promising sales potential<br />
- Make more informed business decisions from insightful <strong>and</strong> in-depth analysis of<br />
<strong>Lonsurf</strong> performance<br />
- Obtain sales forecast for <strong>Lonsurf</strong> from 2013-<strong>2023</strong> in <strong>to</strong>p eight countries (the US,<br />
France, Germany, Italy, Spain, the UK, Japan <strong>and</strong> China)<br />
For More Information Visit : www.aarks<strong>to</strong>re.com
Table of Content<br />
1. INTRODUCTION<br />
2. Disease Overview<br />
3. Disease Management<br />
4. Competitive Assessment<br />
5. <strong>Lonsurf</strong><br />
6.Appendix<br />
For More Information Visit : www.aarks<strong>to</strong>re.com
List Of Tables<br />
Table 1: TNM <strong>and</strong> Staging Classification System for CRC 15<br />
Table 2: Symp<strong>to</strong>ms of <strong>Colorectal</strong> <strong>Cancer</strong> 16<br />
Table 3: Treatment Guidelines for CRC 21<br />
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the<br />
Global <strong>Market</strong>s, 2013 22<br />
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the<br />
Global <strong>Market</strong>s, 2013 23<br />
Table 6: Leading Treatments for CRC, 2014 32<br />
Table 7: Product Profile - <strong>Lonsurf</strong> 35<br />
Table 8: <strong>Lonsurf</strong> SWOT <strong>Analysis</strong>, 2014 37<br />
Table 9: Global Sales <strong>Forecast</strong>s ($m) for <strong>Lonsurf</strong> (TAS-102), 2013-<strong>2023</strong> 38<br />
Table 10: Average Body Weight <strong>and</strong> Surface Area Across the 8MM 49<br />
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 53<br />
For More Information Visit : www.aarks<strong>to</strong>re.com
Related Reports<br />
• Global Telemedicine market report<br />
• Global Clinical trial outsourcing report<br />
• Latest Chinese Guidance for Development, Evaluation, License Approval<br />
of Biosimilars<br />
• 2015 Strategies in the Global Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />
• 2015 Strategies in the European Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry<br />
<strong>Market</strong>s<br />
• 2015 Strategies in the French Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />
• 2015 Strategies in the German Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />
• 2015 Strategies in the Italian Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />
• 2015 Strategies in the Japanese Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />
• 2015 Strategies in the Spanish Hema<strong>to</strong>logy <strong>and</strong> Flow Cy<strong>to</strong>metry <strong>Market</strong>s<br />
For More Information Visit : www.aarks<strong>to</strong>re.com
Follow Us<br />
https://www.facebook.com/aarks<strong>to</strong>redotcom<br />
https://twitter.com/aarks<strong>to</strong>re<br />
https://plus.google.com/+<strong>Aarks<strong>to</strong>re</strong>dotcom/posts<br />
https://www.linkedin.com/company/aarks<strong>to</strong>re-enterprise<br />
For More Information Visit : www.aarks<strong>to</strong>re.com
Contact Us<br />
Office Address<br />
Office No. - 809, 8th Floor,<br />
B-Wing, Mahaavir Icon,<br />
Plot No.- 89 & 90, Sec<strong>to</strong>r-15,<br />
CBD-Belapur, Navi Mumbai – 400614,<br />
Maharashtra, India.<br />
Mail us at contact@aarks<strong>to</strong>re.com<br />
24/7 Online Support: +91 9987295242<br />
General Inquiries : +91 - 22 2756 4953<br />
For More Information Visit : www.aarks<strong>to</strong>re.com